Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX?
Osteoporosis International, 06/24/09
Adler RA et al. – Study demonstrates that dual-energy X-ray absorptiometry (DXA) and new fracture prediction algorithm (FRAX™) tool with corrected femoral neck T-score identify different men on androgen deprivation therapy (ADT) for treatment of osteoporosis.
Methods- Study determines if the new fracture prediction method, FRAX™, which is based on femoral neck DXA plus risk factors could determine which men should receive osteoporosis therapy
- Of 115 men undergoing ADT referred for DXA testing, those with BMD in spine, hip, or forearm of ≥2.5 standard deviations were considered treatment candidates
- Using FRAX™ with and w/o femoral neck BMD, men were treatment candidates if the 10-yr hip fracture risk was ≥3% or the major osteoporotic fracture risk was ≥20%
- Men averaged 77 yrs old; 58% were African–American, and 14.8% were current smokers
- Mean femoral neck T-score was -1.4
- Using DXA, 38 (33%) men would need treatment
- When FRAX™ was calculated including the femoral neck T-score, only 20 men met criteria for treatment
- However, when FRAX™ was calculated without the T-score, 62 men met criteria for treatment
- Overlap among the groups was surprisingly modest
Today in Bone Metabolism...keeping you current
Receive free subspecialty "5-minute updates" via email
Bisphosphonate therapy: When not to monitor BMD
The Journal of Family Practice, 11/02/09
Cardiovascular diseases and risk of hip fracture
JAMA, 10/23/09
Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial
Osteoporosis International, 10/06/09
Sponsor
Article Search
Sponsor


See Latest Articles


